SERCA2a: its role in the development of heart failure and as a potential therapeutic target

The complexity of heart physiology has delayed the implementation of efficient, feasible, and safe therapies to fight against heart diseases for many years. As knowledge of the precise mechanisms governing cardiac hypertrophy and heart failure development increases, the availability of new therapeut...

Full description

Saved in:
Bibliographic Details
Published inResearch reports in clinical cardiology Vol. 5; no. default; pp. 43 - 55
Main Authors Fragoso-Medina, Jorge, Zarain-Herzberg, Angel
Format Journal Article
LanguageEnglish
Published Macclesfield Dove Medical Press Limited 01.01.2014
Taylor & Francis Ltd
Dove Medical Press
Subjects
Adenosine
Binding sites
Cardiomyocytes
Cardiomyopathy
Care and treatment
Development and progression
Diabetes
Gene expression
Gene mutation
Gene therapy
Genetic aspects
Heart failure
Kinases
Physiology
Proteins
Transcription factors
Mexico
Online AccessGet full text

Cover

More Information
Summary:The complexity of heart physiology has delayed the implementation of efficient, feasible, and safe therapies to fight against heart diseases for many years. As knowledge of the precise mechanisms governing cardiac hypertrophy and heart failure development increases, the availability of new therapeutic alternatives also grows. Since the cardiomyocyte physiology deeply depends on the correct calcium handling, many efforts to describe accurately the excitation-contraction coupling process in the heart and the proteins involved have been made. Among the proteins participating in calcium handling, sarco/endoplasmic reticulum [Ca.sup.2+] adenosine triphosphatase-2a (SERCA2a), whose expression and function is decreased in heart failure, stands out because of its critical role regulating [Ca.sup.2+] concentration in the cardiomyocyte. The importance of SERCA2a has been reflected in numerous studies aimed to describe its expression and function. Recently, gene therapy to deliver SERCA2a has shown promising results in human clinical trials. This paper reviews the current literature knowledge exploring diverse approaches to rescue SERCA2a expression in heart failure. It also discusses some data suggesting other possible therapies that could improve SERCA2a expression and function in cardiac diseases. Keywords: SERCA2a, cardiac hypertrophy, heart failure, gene therapy, calcium
ISSN:1179-8475
1179-8475
DOI:10.2147/RRCC.S38614